MGC Pharmaceuticals Ltd (ASX:MXC) co-founder and MD Roby Zamer is set to present on its achievements including the latest pre-clinical in-vitro laboratory results at Proactive cannabis webinar on Tuesday, August 11.
The company's shares surged 41% this morning after the results confirmed the effective immunological activity for the use of ArtemiC as an immune-modulatory agent for the treatment of COVID-19.
Further studies are underway and planned to augment these initial findings to evaluate the preferable ratios between the active ingredients.
MGC is currently awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial underway in Israel, which are expected to be finalised shortly.
Co-founder and MD Roby Zamer
Two leading cannabinoid medicinal products
The European-based bio pharma company creates premium phytocannabinoid-based products from its GMP facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.
The company has two leading cannabinoid medicinal products in late-stage development – CannEpil®, an oral oil solution treatment for refractory epilepsy and CogniCann®, an oral spray for relief of dementia symptoms.
With facilities in Australia, Slovenia and the Czech Republic, MGC Pharmas mission is to build an innovative company that provides affordable phytocannabinoid medicines for targeted global markets and patients.
Three companies to present
Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins will present on the companys access to the world largest and fastest growing cannabis markets and Southern Cannabis Holdings director and CEO Tim DrRead More – Source